Sirolimus alternatives: what the evidence actually supports

Last updated 2026-07-30

What counts as a real alternative to sirolimus for longevity use?

A true alternative would need to do what off-label sirolimus is supposed to do: extend healthy lifespan by acting on the mTOR pathway or a related nutrient-sensing pathway, with some evidence base behind it. That narrows the field fast. Most things marketed as "rapamycin alternatives" (resveratrol, NMN, various supplements) don't hit mTOR the same way and don't have comparable animal data. The honest list of candidates with actual research behind them is short: other rapalogs (everolimus), acarbose, metformin, 17-alpha-estradiol (males only), and a handful of NAD+ precursor compounds with much thinner evidence. None of these have a completed human trial showing extended lifespan or healthspan in people. That's true of sirolimus itself, too. The National Institute on Aging runs the Interventions Testing Program (ITP), which has tested dozens of compounds in genetically diverse mice across three labs since 2004. Rapamycin is the only compound in that program to extend lifespan in every cohort tested, at multiple doses, in both sexes ^[1]. That's why it dominates the longevity conversation. It's not that rapamycin is proven in humans. It's that it's the best-supported candidate in animals, by a wide margin, and nothing else on this list is close. If you're trying to decide between sirolimus and something else, the real question isn't "which one works," because none of them has human proof. It's "which one has the strongest animal signal and the risk profile I can live with." For background on what the human evidence for sirolimus itself actually looks like, see sirolimus reviews and is sirolimus worth it.

Are sirolimus and rapamycin different drugs, or the same alternative to each other?

They're the same molecule. Sirolimus is the generic name; rapamycin is the older, original name from when it was isolated from soil bacteria on Easter Island (Rapa Nui) in the 1970s. Rapamune is the branded formulation. Fyarro (albumin-bound sirolimus) and Hyftor (topical sirolimus) are newer FDA-approved products for specific conditions, not longevity ^{[2] [3]}. So when someone asks about "sirolimus alternatives," they usually mean one of three things: a different drug entirely (metformin, acarbose), a chemical cousin of rapamycin (a rapalog like everolimus), or a different dosing approach to sirolimus itself (daily versus weekly, generic versus brand). Only the first category is a true alternative. The second and third are variations on the same drug. This matters because if someone is reacting badly to sirolimus (mouth ulcers, for instance) and switches to everolimus expecting a different experience, they're often disappointed. Everolimus hits the same mTOR complex through a similar mechanism and carries overlapping side effects, plus it's approved for cancer and transplant indications with its own dosing complexity, not something typically compounded or prescribed off-label for longevity.

How does rapamycin compare to everolimus as an mTOR inhibitor?

Everolimus is a rapamycin analog (a "rapalog") with a shorter half-life, roughly 30 hours versus sirolimus's 62 hours ^[4]. Both inhibit mTORC1. Everolimus is FDA-approved for several cancers, for immunosuppression after organ transplant, and for tuberous sclerosis-related conditions, but it has no longevity indication and essentially no off-label longevity dosing culture the way sirolimus does. There is one directly relevant human study here, and it's worth knowing because it's the closest thing to human mTOR-and-aging data that exists. A 2014 Novartis-sponsored trial (Mannick et al., published in Science Translational Medicine) gave low-dose everolimus or a rapalog (RAD001) to elderly adults for six weeks and found improved response to influenza vaccination compared to placebo, an immune function readout used as a proxy for immune aging ^[5]. It's a six-week immune study, not a lifespan trial, and it doesn't tell you anything about mortality or healthspan over years. But it's frequently cited (sometimes overstated) as "human proof" for mTOR inhibition and aging. It isn't proof of a longevity effect. It's a hint that the pathway is druggable in older humans without catastrophic near-term harm at low, intermittent doses. For someone comparing the two drugs directly: sirolimus has decades more clinical use, a large off-label longevity community with informal dosing protocols, and it's what the NIA mouse data is built around. Everolimus has less real-world off-label use for aging and isn't typically what compounding pharmacies or longevity-focused prescribers reach for. There's no evidence one is safer or more effective than the other for longevity purposes, because neither has been tested for that purpose in a real human trial.

Does metformin work as well as sirolimus for longevity?

No, and the evidence gap is bigger than most people think. Metformin is a diabetes drug that activates AMPK and has an epidemiological association (not a randomized trial) with lower mortality in diabetics compared to non-diabetics in some observational studies. That's a weak form of evidence, prone to "healthy user" bias. The much-discussed TAME trial (Targeting Aging with Metformin) was designed to test whether metformin delays age-related disease onset in non-diabetic adults 65-79. It has not been completed and, as of 2024, was still working through funding; TAME has not reported lifespan or healthspan results in humans. There is no completed human metformin longevity trial, same gap as sirolimus. In the NIA Interventions Testing Program itself, metformin alone did not extend lifespan in mice at the doses tested; a metformin-plus-rapamycin combination did extend lifespan, but the effect was attributed to rapamycin, and metformin alone was not a survival winner in that program's published results ^{[1] [6]}. This is a genuinely important, underappreciated point: rapamycin's mouse data is stronger than metformin's mouse data. Metformin has better name recognition and a longer safety record in humans (it's been prescribed for type 2 diabetes since the 1950s), but recognition isn't the same as evidence of a longevity effect.

What about acarbose, the other top performer in the NIA mouse studies?

Acarbose is a real second option worth knowing about, because it's the only other compound to show a reproducible lifespan extension in the same NIA Interventions Testing Program that anchors the rapamycin case. Acarbose extended median lifespan in male mice by about 20% and in female mice by a smaller amount in ITP cohorts, an effect size clearly behind rapamycin's roughly 25% extension in females at higher doses, but still statistically real and reproduced across cohorts ^{[1] [6]}. Acarbose is an alpha-glucosidase inhibitor, approved by the FDA for type 2 diabetes since 1995, and works by blunting the blood glucose spike after carbohydrate meals. Its side effects are gastrointestinal (gas, bloating, diarrhea) rather than immunosuppressive, which is a real practical advantage over sirolimus for someone worried about infection risk. The catch: there's no human longevity trial for acarbose either. It has decades of safety data as a diabetes drug, which is more reassuring than what exists for off-label rapamycin dosing schedules, but "safe for glucose control" and "extends healthy lifespan in humans" are different claims, and only the first one has real support. Here's a comparison of where the actual evidence stands for the most-discussed candidates: | Compound | FDA-approved for | Mouse lifespan data (NIA ITP) | Completed human lifespan trial | Main off-label risk |

Is 17-alpha-estradiol a real alternative, or is it niche?

It's real in the mouse data and niche in practical use. 17-alpha-estradiol is a non-feminizing form of estrogen that extended lifespan in male mice in NIA ITP studies, with essentially no effect in female mice ^[1]. That sex-specific result is itself a clue about how different these pathways can be between males and females, something the rapamycin data also shows to a lesser degree (rapamycin's effect size differs by sex and dose in the ITP cohorts). There's no meaningful human safety or dosing literature for 17-alpha-estradiol as a longevity intervention. It shows up in biohacker forums more than in any clinical protocol, and no prescriber network or compounding pathway treats it the way sirolimus has one. If you're weighing real options today, this one isn't practically available in the way sirolimus is, and the sex-limited effect makes it irrelevant for half the population anyway.

Do NAD+ boosters (NMN, NR) work as sirolimus alternatives?

They target a different pathway (NAD+ salvage, sirtuins) rather than mTOR, so they're not really an alternative in the mechanistic sense, more a different bet entirely. The evidence is also thinner. Small human trials of NMN and NR have shown they raise blood NAD+ levels and are generally well tolerated at studied doses, but no trial has shown a healthspan or lifespan effect in humans, and the NIA Interventions Testing Program has not reported the same reproducible lifespan extension for NMN or NR that it has for rapamycin or acarbose ^[1]. A 2021 randomized trial of nicotinamide riboside in older adults found it safe and effective at raising NAD+ levels over 6 weeks, but did not measure or claim any lifespan or aging-outcome benefit ^[7]. That's the pattern across this whole category: safety and biomarker data, no outcome data. If your goal is specifically "an evidence-based mTOR-pathway longevity approach," NAD+ precursors aren't answering that question at all. If your goal is broader "anything that might help me age well," they're a much lower-cost, lower-risk experiment than sirolimus, just without a comparable animal survival signal behind them.

What are the real risks of sirolimus that make people look for alternatives?

Three risk categories drive most of the search for alternatives, and they're all real, documented effects of mTOR inhibition, not rare idiosyncratic reactions. Immunosuppression is the core one, because it's mechanistically inseparable from what makes rapamycin work in mice: mTOR inhibition dampens certain immune signaling pathways. At transplant doses, sirolimus carries an FDA boxed warning about increased risk of infection and malignancy ^[4]. At the much lower, intermittent doses used off-label for longevity (commonly once weekly), the practical risk is more modest but not zero, and it's the primary reason prescribers ask about vaccination status, current infections, and travel plans before starting. Mouth ulcers (stomatitis) are the most common complaint in both transplant-dose and off-label low-dose users. They're listed in the Rapamune prescribing information as a common adverse reaction and are frequently reported in the off-label longevity community as the main reason people reduce dose or switch to a different schedule ^[4]. Metabolic effects are the third bucket: sirolimus can raise LDL cholesterol and triglycerides and has been associated with new-onset insulin resistance in some transplant populations, effects documented in the FDA label and in transplant literature ^{[4] [4]}. For someone already managing lipids or glucose, this is a real tradeoff to discuss with a prescriber, and it's part of why routine labs (lipid panel, fasting glucose, CBC) are standard before and during off-label use. None of the alternatives above are risk-free either. Acarbose trades immunosuppression risk for GI side effects. Metformin carries a small risk of B12 deficiency with long-term use. Understanding your own risk tolerance matters more than chasing a mythically safer option, because none of these drugs has been through the kind of long-term human safety study that would let anyone say definitively which is safest for healthy aging use. For a fuller risk breakdown, see sirolimus pros and cons.

Why is there still no human lifespan trial for sirolimus or any alternative?

Because a lifespan trial in healthy humans is enormous, slow, and expensive in a way that doesn't fit normal drug development funding. To detect a modest lifespan extension, you'd need thousands of participants followed for years, likely a decade or more, with all the cost and dropout problems that come with a trial that long. No pharmaceutical company has commercial incentive to fund this, because there's no FDA-approved indication called "aging" to sell against; the FDA does not currently recognize aging itself as a treatable indication ^[8]. That's why the field has settled for proxy endpoints. The TAME trial for metformin was specifically designed around a composite endpoint of new age-related diseases (rather than raw mortality) to make the trial size and timeline more feasible, and even that scaled-down design has struggled to secure full funding. The everolimus immune-function study used vaccine response after six weeks as a stand-in for the whole aging process, not lifespan ^[5]. For sirolimus specifically, what exists instead is a growing body of observational data and small human trials on biomarkers, like the PEARL trial, a 2023 randomized, placebo-controlled trial of low-dose rapamycin in healthy adults that measured safety and some functional outcomes over 48 weeks, not mortality or disease incidence over years . It's a genuinely useful safety and tolerability study, one of the better human rapamycin trials that exists, but it's not a lifespan trial and the authors don't claim it is. So the honest state of the science, for sirolimus and every alternative on this page, is: strong-to-moderate animal data, some short human safety and biomarker data, zero completed human lifespan or healthspan outcome trials. Anyone selling you certainty beyond that is overstating the evidence. Our sirolimus results timeline and sirolimus success rate pages go through what the available human data does and doesn't show in more detail.

How do you actually choose between sirolimus and an alternative?

Start with what you're optimizing for, because the honest answer is that no option here has proof of working, only different strengths of animal and short-term human evidence. If you want the strongest, most reproduced animal survival signal and are comfortable with periodic bloodwork and provider oversight, sirolimus has the deepest mouse evidence base of anything on this list, from a federally funded program specifically designed to find and replicate longevity effects across labs ^[1]. If immunosuppression risk is your main concern and you're willing to accept a smaller mouse effect size, acarbose is the most evidence-backed alternative, with decades of separate safety data as an approved diabetes drug. If you want the lowest-cost, lowest-risk experiment and don't need mTOR-pathway evidence specifically, NAD+ precursors or metformin (if you have another reason to be on it, like prediabetes) are reasonable low-stakes choices, just without the mouse lifespan data to back the longevity claim. Whatever you choose, this only makes sense with medical oversight: baseline and follow-up labs, a real conversation about infection risk and vaccination timing, and monitoring for the known metabolic and mouth-ulcer effects. If you're moving forward with sirolimus specifically, the provider-reviewed route through Sirolimus Rx connects you with a licensed prescriber for evaluation and, where appropriate, a prescription filled through a licensed U.S. pharmacy partner, rather than buying from an unverified source. Read sirolimus before and after for what realistic expectations look like on that path.

Frequently asked questions

Is there any human proof that sirolimus extends lifespan?

No. There is no completed human trial measuring lifespan or mortality outcomes for sirolimus. The strongest evidence is in mice from the NIA Interventions Testing Program, which found reproducible lifespan extension across labs and doses ^[1]. Human data is limited to short safety and biomarker trials, like the 48-week PEARL trial, which studied tolerability, not survival ^[14].

What is the closest thing to a proven sirolimus alternative?

Acarbose is the closest, in the sense that it's the only other compound to show reproducible lifespan extension in the same NIA program that anchors the rapamycin data, roughly 20% in male mice ^[1][8]. It still has no completed human lifespan trial, but it has decades of separate safety data as an FDA-approved diabetes drug since 1995.

Can I take metformin instead of sirolimus for longevity?

You can, but the mouse evidence doesn't support it as strongly. In NIA Interventions Testing Program studies, metformin alone did not extend lifespan; it only helped when combined with rapamycin, and that effect was attributed to the rapamycin ^[1][7]. The human TAME trial testing metformin for aging has not been completed ^[6].

Are rapamycin and sirolimus really the same drug?

Yes. Sirolimus is the generic drug name; rapamycin is the original name from its discovery in soil bacteria on Easter Island in the 1970s. Rapamune is the branded oral formulation. Fyarro and Hyftor are newer FDA-approved sirolimus formulations for specific medical conditions, unrelated to longevity use ^[2][3].

Is everolimus safer than sirolimus for off-label longevity use?

There's no evidence it's safer. Everolimus is a rapamycin analog with a shorter half-life (about 30 hours versus 62) but a similar mechanism and overlapping side effects ^[4]. It has essentially no off-label longevity dosing history, so there's less real-world data on how it behaves at low, intermittent doses compared to sirolimus.

What are the biggest risks of off-label sirolimus use?

The three most documented risks are immunosuppression (increased infection risk, flagged in the FDA boxed warning) ^[10], mouth ulcers (stomatitis), which is one of the most commonly reported side effects ^[11], and metabolic changes including elevated LDL cholesterol, triglycerides, and in some cases insulin resistance ^[10][12].

Does acarbose have fewer side effects than sirolimus?

Acarbose's side effects are mostly gastrointestinal (gas, bloating, diarrhea) rather than immunosuppressive, which many people see as a lower-stakes tradeoff. It doesn't carry an infection-risk warning the way sirolimus does. But its mouse lifespan effect is also smaller than rapamycin's in NIA ITP data ^[1][8].

Why hasn't a human lifespan trial for rapamycin been done yet?

Lifespan trials in humans require thousands of participants followed for years, likely a decade or more, with major cost and dropout challenges. The FDA does not currently recognize aging as a treatable indication, so there's no regulatory pathway or commercial incentive driving a company to fund one ^[13].

Is 17-alpha-estradiol a viable alternative to sirolimus?

Only in mouse data, and only for males. It extended lifespan in male mice in NIA ITP studies with no effect in females ^[1]. There's no meaningful human safety or dosing data, and no established prescriber pathway, so it isn't a practical option today the way sirolimus is.

Do NMN or NR work as well as sirolimus for aging?

They target a different pathway (NAD+ salvage) rather than mTOR, so they're not a direct substitute. Small human trials show they raise NAD+ levels safely, but none has shown a lifespan or healthspan benefit, and the NIA ITP hasn't reported the same reproducible mouse lifespan extension seen with rapamycin or acarbose ^[1][9].

Should I combine sirolimus with another longevity compound?

Only under medical guidance. The NIA ITP found that combining rapamycin and metformin extended mouse lifespan, but attributed the effect to rapamycin, and there's no human trial testing any combination for aging outcomes ^[1][7]. Combining drugs off-label without monitoring adds risk without added proof of benefit.

What should I ask a doctor before choosing between sirolimus and an alternative?

Ask about your baseline labs (lipids, glucose, CBC), current infection and vaccination status, any history of high cholesterol or immune issues, and what monitoring schedule they recommend. Ask them directly what human data exists for whichever drug you're considering, since for all of these, it's less than people assume.

Sources

1. National Institute on Aging, Interventions Testing Program: Rapamycin extends lifespan in genetically diverse mice across multiple cohorts, doses, and both sexes; acarbose and 17-alpha-estradiol also show reproducible lifespan extension
2. FDA, Fyarro approval: Fyarro (sirolimus protein-bound particles) is FDA-approved for a specific rare cancer indication, not longevity
3. FDA, Hyftor approval: Hyftor (topical sirolimus) is FDA-approved for facial angiofibroma in tuberous sclerosis complex
4. FDA label, Rapamune (sirolimus): Sirolimus has an elimination half-life of approximately 62 hours
5. Mannick et al., Science Translational Medicine, 2014: Low-dose mTOR inhibitor RAD001/everolimus improved influenza vaccine response in elderly adults over a 6-week study
6. Strong et al., Aging Cell, 2016 (NIA ITP): Metformin combined with rapamycin extended mouse lifespan in ITP studies, with the effect attributed primarily to rapamycin
7. Martens et al., Nature Communications, 2018: Nicotinamide riboside supplementation safely increased NAD+ metabolome in healthy middle-aged and older adults over 6 weeks without measuring lifespan outcomes
8. FDA, Aging - not an approvable indication under current framework: The FDA does not currently recognize aging itself as a treatable indication under its standard drug approval framework